Prostate cancer cell

Prostate cancer cells are malignant cells arising from the glandular epithelium of the prostate, primarily driven by androgen signaling pathways mediated through the androgen receptor [1][2]. These cells are characterized by dysregulated growth, evasion of apoptotic signals, and a high propensity for bone metastasis, which remains a significant clinical challenge [2][3]. Although 'prostate cancer cells' represent a complex cell population rather than a single molecular target, they are identified and treated via specific cell-surface and intracellular markers, most notably the Androgen Receptor (AR) and Prostate-Specific Membrane Antigen (PSMA) [4][5]. Therapeutic interventions aim to eliminate these cells or arrest their growth through androgen deprivation, competitive receptor antagonism, or the delivery of cytotoxic or radioactive payloads via targeted ligands [6]. Over the course of treatment, these cells often evolve resistance mechanisms, such as AR amplification, mutations, or alternative splicing (e.g., AR-V7), necessitating multi-modal treatment strategies and the use of precise biomarkers to monitor therapeutic efficacy [7][8].

Other names

Prostate carcinoma cellMalignant prostate cellPCa cellProstate adenocarcinoma cell

Drugs targeting these cells primarily function by antagonizing the androgen receptor, inhibiting steroid biosynthesis, disrupting microtubule-mediated mitosis, or delivering targeted alpha or beta radiation to cell-surface markers such as PSMA.